Shares of Annovis Bio Inc. (ANVS) have experienced a 70% decline from their 52-week high of $22.49, reached in December last year, and trade around $6.
This clinical-stage, drug platform company is focused on addressing neurodegeneration, such as Alzheimer's Disease, Parkinson's Disease, and other chronic neurodegenerative diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com